The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity.

Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol (2010) 2.36

Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal (2012) 1.37

Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships. PLoS One (2014) 0.78

Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties. PLoS One (2014) 0.77

Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury. Oxid Med Cell Longev (2015) 0.75

In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS One (2015) 0.75

A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36

The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev (2005) 2.22

Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem (2006) 2.04

Preanalytical quality improvement: from dream to reality. Clin Chem Lab Med (2011) 2.01

Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood (2004) 2.00

Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep (2009) 1.97

Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity. J Biol Inorg Chem (2005) 1.96

The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta (2002) 1.86

Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood (2004) 1.67

Iron uptake and metabolism in the new millennium. Trends Cell Biol (2006) 1.66

Preanalytical quality improvement: in quality we trust. Clin Chem Lab Med (2013) 1.52

Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med (2008) 1.50

The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis (2006) 1.49

Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur J Heart Fail (2004) 1.49

N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS One (2013) 1.46

Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem (2009) 1.43

Growth arrest and DNA damage-45 alpha (GADD45alpha). Int J Biochem Cell Biol (2008) 1.43

Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood (2004) 1.42

The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol (2002) 1.40

Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol (2003) 1.38

The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem (2012) 1.38

Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci U S A (2009) 1.31

Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res (2003) 1.30

Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. Inorg Chem (2006) 1.30

Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood (2002) 1.29

Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res (2006) 1.28

Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res (2011) 1.28

SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol (2005) 1.25

Causes, consequences, detection, and prevention of identification errors in laboratory diagnostics. Clin Chem Lab Med (2009) 1.25

Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol (2013) 1.25

Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol (2008) 1.24

The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Natl Acad Sci U S A (2008) 1.22

Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol (2010) 1.21

Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol (2010) 1.21

EQUAL-quant: an international external quality assessment scheme for real-time PCR. Clin Chem (2006) 1.20

Multicenter evaluation of the hemolysis index in automated clinical chemistry systems. Clin Chem Lab Med (2009) 1.20

Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood (2007) 1.19

Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood (2009) 1.18

Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde. Acta Crystallogr C (2003) 1.17

The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis (2011) 1.17

Novel chelators for cancer treatment: where are we now? Antioxid Redox Signal (2012) 1.16

In vitro analysis of iron chelating activity of flavonoids. J Inorg Biochem (2011) 1.16

Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood (2006) 1.15

The role of reactive oxygen and nitrogen species in cellular iron metabolism. Free Radic Res (2006) 1.14

Tuning cell cycle regulation with an iron key. Cell Cycle (2007) 1.13

The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J (2009) 1.12

Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites. Int J Biochem Cell Biol (2004) 1.11

Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology (2007) 1.11

Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol (2011) 1.11

Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chem Res Toxicol (2007) 1.10

The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid Redox Signal (2012) 1.09

Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med Chem (2007) 1.09

The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol (2012) 1.08

Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proc Natl Acad Sci U S A (2006) 1.06

Expression and activity of vitamin D receptor in the human placenta and in choriocarcinoma BeWo and JEG-3 cell lines. Mol Cell Endocrinol (2008) 1.06

Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem (2010) 1.05

Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol Pharmacol (2009) 1.05

Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome. Clin Chem Lab Med (2008) 1.04

Thiosemicarbazones: the new wave in cancer treatment. Future Med Chem (2009) 1.03

The translational regulator eIF3a: the tricky eIF3 subunit! Biochim Biophys Acta (2010) 1.02

P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem (2013) 1.01

Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism. Biochim Biophys Acta (2013) 1.00

Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy. Bioorg Med Chem Lett (2012) 0.99

Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy. Bioorg Med Chem Lett (2012) 0.99

Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism. Proteomics (2008) 0.99

Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem (2011) 0.98

Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series. J Med Chem (2007) 0.98

Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron. Biochem J (2003) 0.98

Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity. Free Radic Biol Med (2010) 0.98

EQUAL-qual: a European program for external quality assessment of genomic DNA extraction and PCR amplification. Clin Chem (2007) 0.97

Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J Med Chem (2012) 0.97

Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. Proc Natl Acad Sci U S A (2012) 0.97

Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. Mol Pharmacol (2012) 0.96

Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J Med Chem (2009) 0.96

Investigating biological activity spectrum for novel quinoline analogues. Bioorg Med Chem (2006) 0.96

Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochim Biophys Acta (2007) 0.95

Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. J Biol Inorg Chem (2003) 0.95

The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity. Mol Pharmacol (2011) 0.95

Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br J Pharmacol (2003) 0.95

2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J Med Chem (2009) 0.95

The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets. Biochim Biophys Acta (2008) 0.95

Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin Cancer Res (2004) 0.95